Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

4 February 2024

Salaheldin Ahmed, Abdulla Ahmed, Göran Rådegran 

https://doi.org/10.1002/pul2.12340

Abstract

To the editor, 

Pulmonary hypertension (PH) is a common condition, present in up to 10% in individuals aged >65 years.1 Whitin this entity, pulmonary arterial hypertension (PAH; group I PH) and chronic thromboembolic pulmonary hypertension (CTEPH; group 4 PH) comprise two rare, but detrimental conditions characterized by pulmonary vasculopathies and remodeling of pulmonary arteries, leading ultimately to right heart failure and death.2 These conditions are accompanied by high morbidity and mortality, for which early diagnosis and treatment initiation are paramount to improve outcome.3

Read the full letter to the editor

Share:

Other materials on this topic

4 May 2021

Virtual poster discussion session one

  • Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin, Iona Cuthbertson
  • Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension, Prakash Chelladurai
  • Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension, Charifa Awada 
  • Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats, Barbora Kaftanová 
  • Endothelial overexpression of sirt3 protects the metabolic etiology in PAH, Anandharajan Rathinasabapath
  • Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension, Tatyana Novoyatleva 
  • Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry, Katherine Kearney Graham 
  • Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH), Richard Channick
  • Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects, Pietro Nardelli
  • Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease, Victor Tapson
  • Acetazolamide and high altitude pulmonary edema prevention, Erik Swenson 
  • Telomeric Tankyrases: a novel and propitious target to ameliorate the maladaptation phenomena at heights, Manjula Miglani 
PVRI Digital Webinar Series
Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view

More from Pulmonary Circulation

Show more details

A collection of up-to-date abstracts from our premier, international, peer-reviewed, medical research journal dedicated exclusively to pulmonary circulation and pulmonary vascular disease. 

Pulmonary vascular disease, environmental pollution, and climate change
Human pulmonary microvascular endothelial cells respond to DAMPs from injured renal tubular cells
Creating a digital approach for promoting physical activity in pediatric pulmonary hypertension: A framework for future interventions
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary disease without pulmonary hypertension
A systematic review of the impact of pulmonary thromboendarterectomy on health-related quality of life
Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross-sectional scientific survey (CLARITY)
Ruptured pulmonary arteriovenous fistula causing hemothorax in a patient with hereditary hemorrhagic telangiectasia: A case report
A perfectly imperfect engine: Utilizing the digital twin paradigm in pulmonary hypertension
Nonsurgical treatment of a patient with decompensated right ventricular failure due to chronic thromboembolic pulmonary hypertension with proximal clot location—A case report
The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: Diagnosis, symptoms, impacts, and treatments
Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real-world data analysis
Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP)
Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension
Association of mildly elevated pulmonary vascular resistance with major cardiovascular events in pulmonary hypertension and chronic kidney disease: A retrospective cohort analysis
Evaluating the technical use of a Fitbit during an intervention for patients with pulmonary arterial hypertension with quality of life as primary endpoint: Lessons learned from the UPHILL study